(VIANEWS) – CONTEXTVISION (CONTX.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CONTEXTVISION (CONTX.OL) | kr7.58 | 3.46% | 61.1% |
| VISTIN PHARMA (VISTN.OL) | kr23.40 | 3.11% | 16.03% |
| VIRBAC (VIRP.PA) | €345.50 | 0.49% | 13.8% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CONTEXTVISION (CONTX.OL)
3.46% Forward Dividend Yield and 61.1% Return On Equity
ContextVision AB (publ), a medical technology software company, provides image analysis and imaging for medical systems in Asia, Europe, and the United States. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and veterinary. Its products include Rivent that offers unparalleled image quality for various types of ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; Rivent Mobile, an enhancing ultrasound image for the handheld ultrasound devices using mobile phones and tablets; and Rivent 3D, an image enhancement product for 3D ultrasound. The company also provides Altumira/Altumira Plus, a platform for digital radiography; and Orthopedic Package for orthopedic imaging. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI. The company was founded in 1983 and is headquartered in Stockholm, Sweden.
Earnings Per Share
As for profitability, CONTEXTVISION has a trailing twelve months EPS of kr0.47.
PE Ratio
CONTEXTVISION has a trailing twelve months price to earnings ratio of 16.13. Meaning, the purchaser of the share is investing kr16.13 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.1%.
Sales Growth
CONTEXTVISION’s sales growth for the current quarter is 29.8%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Nov 2, 2023, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 3.46%.
Moving Average
CONTEXTVISION’s value is below its 50-day moving average of kr8.37 and way under its 200-day moving average of kr8.72.
More news about CONTEXTVISION.
2. VISTIN PHARMA (VISTN.OL)
3.11% Forward Dividend Yield and 16.03% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 23.4. Meaning, the purchaser of the share is investing kr23.4 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Volatility
VISTIN PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.28%, a positive 0.07%, and a positive 1.93%.
VISTIN PHARMA’s highest amplitude of average volatility was 1.42% (last week), 1.65% (last month), and 1.93% (last quarter).
More news about VISTIN PHARMA.
3. VIRBAC (VIRP.PA)
0.49% Forward Dividend Yield and 13.8% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.13.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.45. Meaning, the purchaser of the share is investing €24.45 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.8%.
Yearly Top and Bottom Value
VIRBAC’s stock is valued at €345.50 at 11:30 EST, way above its 52-week high of €314.00.
Volume
Today’s last reported volume for VIRBAC is 309 which is 93.21% below its average volume of 4556.
More news about VIRBAC.
